AbbVie's upadacitinib successful in third late-stage dermatitis study (NYSE:ABBV
published 28.07.2020 11:20
AbbVie (NYSE:ABBV) announces another successful Phase 3 clinical trial, AD Up, evaluating Rinvoq (upadacitinib) plus topical corticosteroids (TCS) in adults and adolescents with moderate-to-severe atopic dermatitis.
Specifically, 77% of patients receiving 30 mg of upadacitinib plus TCS achieved EASI 75 (75% improvement in EASI score) compared to 26% in the placebo arm.
59% of patients in the cohort achieved clear or almost clear skin compared to 11% in the control arm.
64% experienced at least a four-grade improvement in itchy skin compared to 15% in the control arm.
Two previous Phase 3s, MEASURE Up 1 & MEASURE Up 2, were also successful.